Glaxosmithkline Plc (GSK) -0.65

Trade GSK
NOW!
Last Trade:38.57Short Ratio:1.50
Last Trade Time:4:01pmDay Range:38.37 - 38.73
Ask:Year Range:28.67 - 43.47
Bid:One Year Target:42.06
Open:38.57Exchange:NYSE
Volume:2743130EBITDA:16.026B
Prev. Close:39.22Market Cap:97.837B
50 Day Moving:38.1136Div Yield:4.93
200 day moving:40.1922PE:12.07

Related RealMoney articles from TheStreet.com

'Mad Money Lightning Round': Keep Raytheon
Cramer's 'Mad Money' Recap: Preparing for the Selloff (Final)
TV Advertising Done Right for Small Business
Five Dumbest Things on Wall Street: Feb. 26
Senate Report: Glaxo Knew of Avandia Risks

Research and Markets: Mexico Pharmaceuticals and Healthcare Report Q2 2010

Posted on 03/19/10 at 9:18am
DUBLIN--(BUSINESS WIRE)-- Research and Markets (
Click here to read the rest of the article

Mad Money Lightning Round! (RTN, NABI, PALM, GSK, FLEX, MDRX, COH, FLIR)

Posted on 03/18/10 at 6:56pm
Tonight on Mad Money, Jim Cramer offered up his opinion on an array of stocks (like every night) during the Lightning Round. Below, is a summary of his recommendations.
Click here to read the rest of the article
Posted in

Research and Markets: Kazakhstan Pharmaceuticals and Healthcare Report Q1 2010

Posted on 03/18/10 at 10:18am
DUBLIN--(BUSINESS WIRE)-- Research and Markets (
Click here to read the rest of the article

US Stock Futures Mixed (PFE, TEVA, GSK, NKE, NVS, FDX)

Posted on 03/18/10 at 9:04am
US stock futures were mixed today as investors got fidgety on concerns surrounding the duration of a recent rally. The reluctance of Eurozone nations to support debt-reduction initiatives in Greece also heightened investor concerns. While futures on S&P 500 lost 1.2 points to 1,159.80, those on Nasdaq 100 moved down half a point to 1,933.50.
Click here to read the rest of the article
Posted in

SmarTrend research report available on GlaxoSmithKline (NYSE:GSK)

Posted on 03/16/10 at 11:18am
SmarTrend, the proprietary pattern recognition system, has made available a free sample copy of our premium research report on (NYSE: GSK) at http://www.mysmartrend.com/research/
Click here to read the rest of the article

Ligand Announces Approval for Revolade® in Europe

Posted on 03/12/10 at 1:21pm
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for R
Click here to read the rest of the article

GlaxoSmithKline: The Trend Continues Lower (GSK)

Posted on 03/11/10 at 8:30pm
SmarTrend identified a Downtrend for GlaxoSmithKline (NYSE: GSK) on January 08, 2010 at $40.97. In approximately 2 months, GlaxoSmithKline has returned 8.3% as of today's recent price of $37.57.
Click here to read the rest of the article

Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year 2009 Financial Results

Posted on 03/10/10 at 5:03pm
ROCKVILLE, Md., March 10, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced fourth quarter and year-end financial results for the three and twelve month periods ended December 26, 2009.
Click here to read the rest of the article